{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:21:12Z","timestamp":1699402872452},"reference-count":0,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":13183,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1979,12]]},"abstract":"<jats:p>The systemic bioavailability, elimination half\u2010life (t\u00bd), and plasma concentration\u2010response relationships of pamatolol, a relatively cardioselective beta adrenoceptor blocker, have been measured in healthy subjects. Pamatolol is rapidly and completely absorbed after ora! dosing. Elimination t\u00bd ranged from 2.9 to 4.6 hr after oral doses and from 2.2 to 5.6 hr after intravenous doses. There was a clear relationship between log plasma pamatolol concentration and sympathetic blockade assessed by reduction of exercise heart rate. Concentration\u2010response curves were essentially identical after oral and intravenous doses. There is no evidence of a first\u2010pass effect, nor is there any evidence of metabolite activity.<\/jats:p>","DOI":"10.1002\/cpt1979266682","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T02:05:49Z","timestamp":1451959549000},"page":"682-685","source":"Crossref","is-referenced-by-count":1,"title":["Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker"],"prefix":"10.1111","volume":"26","author":[{"given":"S. George","family":"Carruthers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pertti","family":"Pentikainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Hosier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Azarnoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1979266682","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1979266682","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt1979266682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:31:00Z","timestamp":1699363860000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt1979266682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1979,12]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1979,12]]}},"alternative-id":["10.1002\/cpt1979266682"],"URL":"https:\/\/doi.org\/10.1002\/cpt1979266682","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1979,12]]}}}